6-(2-nitrobenzoylamino)-1-phenyl-9H-pyrido<3,4-b>indole | 131203-55-9

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 哈马拉生物碱
• 英文名称: 6-(2-nitrobenzoylamino)-1-phenyl-9H-pyrido<3,4-b>indole
• 英文别名: 2-nitro-N-(1-phenyl-9H-pyrido[3,4-b]indol-6-yl)benzamide
• CAS: 131203-55-9
• 化学式: C₂₄H₁₆N₄O₃
• 分子量: 408.416
• InChiKey: RFGISXPJCQEKJY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  31
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  104
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-(2-nitrobenzoylamino)-1-phenyl-9H-pyrido<3,4-b>indole 在 镍 氢气 作用下， 以 乙醇 为溶剂， 反应 10.0h， 以78.7%的产率得到6-(2-aminobenzoylamino)-1-phenyl-9H-pyrido<3,4-b>indole
  参考文献：
  名称：

  Agarwal; Agarwal; Bhakuni, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1990, vol. 29, # 9, p. 848 - 854

  摘要：

  DOI：
• 作为产物：
  描述：

  1-苯基-9H-吡啶并[3,4-b]吲哚-6-胺 、 2-硝基苯甲酰氯 在 三乙胺 作用下， 以 丙酮 为溶剂， 反应 2.0h， 以96.5%的产率得到6-(2-nitrobenzoylamino)-1-phenyl-9H-pyrido<3,4-b>indole
  参考文献：
  名称：

  Agarwal; Agarwal; Bhakuni, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1990, vol. 29, # 9, p. 848 - 854

  摘要：

  DOI：

文献信息

• Cytidine deaminase expression level in cancer as a new therapeutic target
  申请人：CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

  公开号：US11209421B2

  公开（公告）日：2021-12-28

  The present invention provides an in vitro method for selecting a patient affected with a tumor for a treatment with an antitumor compound, wherein the method comprises a step of measuring the expression level of CDA (Cytidine Deaminase) in a cancer sample from said patient. When the CDA expression level of a cancer sample is lower than the reference expression level, it is indicative that the patient is suitable for a treatment with an antitumor compound selected from the group consisting of the compounds of table 4, in particular aminoflavone. Alternatively, when the CDA expression level of a cancer sample is higher than the reference expression level, it is indicative that the patient is suitable for a treatment with an antitumor compound selected from the group consisting of the compounds of table 3, in particular dasatinib.

  本发明提供了一种选择肿瘤患者接受抗肿瘤化合物治疗的体外方法，其中该方法包括测量所述患者的癌症样本中CDA（胞苷脱氨酶）的表达水平的步骤。当癌症样本的CDA表达水平低于参考表达水平时，表明患者适合使用选自表4化合物组成的组的抗肿瘤化合物，特别是氨基黄酮进行治疗。或者，当癌症样本的CDA表达水平高于参考表达水平时，表明患者适合使用选自表3化合物组成的组的抗肿瘤化合物，特别是达沙替尼进行治疗。
• AGARWAL, ALKA;AGARWAL, SHIV K.;BHAKUNI, D. S.;GUPTA, SUMAN;KATIYAR, J. C., INDIAN J. CHEM. B, 29,(1990) N, C. 848-854
  作者：AGARWAL, ALKA、AGARWAL, SHIV K.、BHAKUNI, D. S.、GUPTA, SUMAN、KATIYAR, J. C.

  DOI：——

  日期：——
• CYTIDINE DEAMINASE EXPRESSION LEVEL IN CANCER AS A NEW THERAPEUTIC TARGET
  申请人：CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

  公开号：US20190293629A1

  公开（公告）日：2019-09-26

  The present invention provides an in vitro method for selecting a patient affected with a tumor for a treatment with an antitumor compound, wherein the method comprises a step of measuring the expression level of CDA (Cytidine Deaminase) in a cancer sample from said patient. When the CDA expression level of a cancer sample is lower than the reference expression level, it is indicative that the patient is suitable for a treatment with an antitumor compound selected from the group consisting of the compounds of table 4, in particular aminoflavone. Alternatively, when the CDA expression level of a cancer sample is higher than the reference expression level, it is indicative that the patient is suitable for a treatment with an antitumor compound selected from the group consisting of the compounds of table 3, in particular dasatinib.
• Agarwal; Agarwal; Bhakuni, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1990, vol. 29, # 9, p. 848 - 854
  作者：Agarwal、Agarwal、Bhakuni

  DOI：——

  日期：——